Literature DB >> 16825392

Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis.

G B Rogers1, M P Carroll, D J Serisier, P M Hockey, G Jones, V Kehagia, G J Connett, K D Bruce.   

Abstract

The bacterial communities present in the oral cavity and the lungs of 19 adult cystic fibrosis (CF) patients were compared by using terminal restriction fragment length polymorphism analysis of 16S rRNA gene PCR products amplified from nucleic acids extracted directly from bacteria in clinical samples. Sputum samples were not found to be subject to profound contamination by oral cavity bacteria. Evidence of colonization of the CF lung by certain oral bacterial species was found.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16825392      PMCID: PMC1489498          DOI: 10.1128/JCM.02282-05

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  9 in total

Review 1.  Role of oral bacteria in respiratory infection.

Authors:  F A Scannapieco
Journal:  J Periodontol       Date:  1999-07       Impact factor: 6.993

Review 2.  Oral health and respiratory infection.

Authors:  Philippe Mojon
Journal:  J Can Dent Assoc       Date:  2002-06       Impact factor: 1.316

3.  Application of terminal RFLP analysis to characterize oral bacterial flora in saliva of healthy subjects and patients with periodontitis.

Authors:  Mitsuo Sakamoto; Yasuo Takeuchi; Makoto Umeda; Isao Ishikawa; Yoshimi Benno
Journal:  J Med Microbiol       Date:  2003-01       Impact factor: 2.472

4.  Characterization of microbial diversity by determining terminal restriction fragment length polymorphisms of genes encoding 16S rRNA.

Authors:  W T Liu; T L Marsh; H Cheng; L J Forney
Journal:  Appl Environ Microbiol       Date:  1997-11       Impact factor: 4.792

5.  Bacterial diversity in human subgingival plaque.

Authors:  B J Paster; S K Boches; J L Galvin; R E Ericson; C N Lau; V A Levanos; A Sahasrabudhe; F E Dewhirst
Journal:  J Bacteriol       Date:  2001-06       Impact factor: 3.490

6.  characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling.

Authors:  G B Rogers; M P Carroll; D J Serisier; P M Hockey; G Jones; K D Bruce
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

7.  Associations between oral conditions and respiratory disease in a national sample survey population.

Authors:  F A Scannapieco; G D Papandonatos; R G Dunford
Journal:  Ann Periodontol       Date:  1998-07

8.  Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling.

Authors:  G B Rogers; C A Hart; J R Mason; M Hughes; M J Walshaw; K D Bruce
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

9.  Bacterial activity in cystic fibrosis lung infections.

Authors:  Geraint B Rogers; Mary P Carroll; David J Serisier; Peter M Hockey; Valia Kehagia; Graeme R Jones; Kenneth D Bruce
Journal:  Respir Res       Date:  2005-06-01
  9 in total
  68 in total

1.  Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures.

Authors:  Edith T Zemanick; Brandie D Wagner; J Kirk Harris; Jeffery S Wagener; Frank J Accurso; Scott D Sagel
Journal:  Pediatr Pulmonol       Date:  2010-06

2.  Identification and management of unusual pathogens in cystic fibrosis.

Authors:  J Stuart Elborn
Journal:  J R Soc Med       Date:  2008-07       Impact factor: 5.344

Review 3.  The role of the bacterial microbiome in lung disease.

Authors:  Robert P Dickson; John R Erb-Downward; Gary B Huffnagle
Journal:  Expert Rev Respir Med       Date:  2013-06       Impact factor: 3.772

4.  Effect of sample storage conditions on culture-independent bacterial community measures in cystic fibrosis sputum specimens.

Authors:  Jiangchao Zhao; Jun Li; Patrick D Schloss; Linda M Kalikin; Tracy A Raymond; Joseph F Petrosino; Vincent B Young; John J LiPuma
Journal:  J Clin Microbiol       Date:  2011-08-24       Impact factor: 5.948

5.  A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients.

Authors:  Christopher D Sibley; Michael D Parkins; Harvey R Rabin; Kangmin Duan; Jens C Norgaard; Michael G Surette
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-23       Impact factor: 11.205

6.  Determining cystic fibrosis-affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling.

Authors:  Geraint B Rogers; Stuart Skelton; David J Serisier; Christopher J van der Gast; Kenneth D Bruce
Journal:  J Clin Microbiol       Date:  2009-11-11       Impact factor: 5.948

Review 7.  Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.

Authors:  Edith T Zemanick; J Kirk Harris; Steven Conway; Michael W Konstan; Bruce Marshall; Alexandra L Quittner; George Retsch-Bogart; Lisa Saiman; Frank J Accurso
Journal:  J Cyst Fibros       Date:  2009-10-14       Impact factor: 5.482

8.  Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients.

Authors:  Michael J Cox; Martin Allgaier; Byron Taylor; Marshall S Baek; Yvonne J Huang; Rebecca A Daly; Ulas Karaoz; Gary L Andersen; Ronald Brown; Kei E Fujimura; Brian Wu; Diem Tran; Jonathan Koff; Mary Ellen Kleinhenz; Dennis Nielson; Eoin L Brodie; Susan V Lynch
Journal:  PLoS One       Date:  2010-06-23       Impact factor: 3.240

9.  Interpreting infective microbiota: the importance of an ecological perspective.

Authors:  Geraint B Rogers; Lucas R Hoffman; Mary P Carroll; Kenneth D Bruce
Journal:  Trends Microbiol       Date:  2013-04-16       Impact factor: 17.079

10.  Metagenomic analysis of respiratory tract DNA viral communities in cystic fibrosis and non-cystic fibrosis individuals.

Authors:  Dana Willner; Mike Furlan; Matthew Haynes; Robert Schmieder; Florent E Angly; Joas Silva; Sassan Tammadoni; Bahador Nosrat; Douglas Conrad; Forest Rohwer
Journal:  PLoS One       Date:  2009-10-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.